{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=49",
    "query": {
      "intervention": "Continuous Dose",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 5326,
    "total_pages": 533,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=50&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=48&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T10:48:31.363Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04839991",
      "title": "Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced and/or Metastatic Solid Tumours"
      ],
      "interventions": [
        {
          "name": "CB307",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crescendo Biologics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2021-06-08",
      "completion_date": "2024-09-25",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04839991"
    },
    {
      "nct_id": "NCT01643382",
      "title": "Hyperglycemia in Renal Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Insulin, Asp(B28)-",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2012-08",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2020-11-05",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01643382"
    },
    {
      "nct_id": "NCT01590082",
      "title": "Doxycycline, Temozolomide and Ipilimumab in Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2012-11",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01590082"
    },
    {
      "nct_id": "NCT00085124",
      "title": "Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "oblimersen sodium",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2003-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Columbus, Ohio",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085124"
    },
    {
      "nct_id": "NCT05127590",
      "title": "RBN-2397 in Combination With Pembrolizumab in Patients With SCCL",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Squamous Non-Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "RBN-2397",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ribon Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-03-15",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 4,
      "location_summary": "Newark, Delaware • Newnan, Georgia • Baton Rouge, Louisiana + 1 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127590"
    },
    {
      "nct_id": "NCT05187182",
      "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastric Cancer",
        "Esophageal Cancer",
        "Stomach Cancer",
        "Esophagus Cancer",
        "Gastroesophageal Junction Cancer"
      ],
      "interventions": [
        {
          "name": "CA-4948",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX7",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2023-06-02",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05187182"
    },
    {
      "nct_id": "NCT05121103",
      "title": "A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma, Refractory",
        "Diffuse Large B-Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma Refractory",
        "Multiple Myeloma in Relapse"
      ],
      "interventions": [
        {
          "name": "EZM0414",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epizyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2022-05-31",
      "completion_date": "2024-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 8,
      "location_summary": "Duarte, California • East Brunswick, New Jersey • New York, New York + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05121103"
    },
    {
      "nct_id": "NCT01712659",
      "title": "Ruxolitinib for Adult T-Cell Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "T Cell Leukemia, Adult",
        "Leukemia, Adult T-Cell",
        "T Cell Leukemia, HTLV I Associated"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2012-10-26",
      "completion_date": "2022-01-18",
      "has_results": true,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712659"
    },
    {
      "nct_id": "NCT00818441",
      "title": "Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-small Cell"
      ],
      "interventions": [
        {
          "name": "Dacomitinib (PF-00299804)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2009-03-11",
      "completion_date": "2015-04-30",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 31,
      "location_summary": "Orange, California • Pleasant Hill, California • Salinas, California + 15 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pleasant Hill",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00818441"
    },
    {
      "nct_id": "NCT03580044",
      "title": "Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Serious Bacterial Infection"
      ],
      "interventions": [
        {
          "name": "ATM-AVI",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "BAT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2020-12-25",
      "completion_date": "2023-01-23",
      "has_results": true,
      "last_update_posted_date": "2024-02-02",
      "last_synced_at": "2026-11-09T10:48:31.363Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03580044"
    }
  ]
}